Cerebrospinal fluid APOE levels: An endophenotype for genetic studies for Alzheimer's disease

Human Molecular Genetics

Volumn 21, Issue 20, 2012, Pages 4558-4571

  Cruchaga, Carlos ^a   Kauwe, John S K ^b   Nowotny, Petra ^a   Bales, Kelly ^c   Pickering, Eve H ^c   Mayo, Kevin ^a   Bertelsen, Sarah ^a   Hinrichs, Anthony ^a   Fagan, Anne M ^a   Holtzman, David M ^a   Morris, John C ^a   Goate, Alison M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BRIGHAM YOUNG UNIVERSITY   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; ENDOPHENOTYPE; FEMALE; GENE MAPPING; GENETIC VARIABILITY; GENOME ANALYSIS; GENOTYPE; HEREDITY; HUMAN; INTRON; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; MENDELIAN RANDOMIZATION ANALYSIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; APOLIPOPROTEINS E; CASE-CONTROL STUDIES; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PHENOTYPE;

EID: 84867119124     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/dds296     Document Type: Article

References (59)

1. Bertram, L., McQueen, M., Mullin, K., Blacker, D. and Tanzi, R. (Accessed 1/26/2012) The AlzGene Database. Alzheimer Research Forum. Available at: http://www.alzgene.org.
2. Kauwe, J.S., Wang, J., Mayo, K., Morris, J.C., Fagan, A.M., Holtzman, D.M. and Goate, A.M. (2009) Alzheimer's disease risk variants show association with cerebrospinal fluid amyloid beta. Neurogenetics, 10, 13-17.
3. Schmechel, D.E., Saunders, A.M., Strittmatter, W.J., Crain, B.J., Hulette, C.M., Joo, S.H., Pericak-Vance, M.A., Goldgaber, D. and Roses, A.D. (1993) Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc. Natl. Acad. Sci. USA., 90, 9649-9653.
4. Morris, J.C., Roe, C.M., Xiong, C., Fagan, A.M., Goate, A.M., Holtzman, D.M. and Mintun, M.A. (2010) APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann. Neurol., 67, 122-131.
5. Fryer, J.D., Demattos, R.B., McCormick, L.M., O'Dell, M.A., Spinner, M.L., Bales, K.R., Paul, S.M., Sullivan, P.M., Parsadanian, M., Bu, G. et al. (2005) The low density lipoprotein receptor regulates the level of central nervous system human and murine apolipoprotein E but does not modify amyloid plaque pathology in PDAPP mice. J. Biol. Chem., 280, 25754-25759.
6. Fryer, J.D., Taylor, J.W., DeMattos, R.B., Bales, K.R., Paul, S.M., Parsadanian, M. and Holtzman, D.M. (2003) Apolipoprotein E markedly facilitates age-dependent cerebral amyloid angiopathy and spontaneous hemorrhage in amyloid precursor protein transgenic mice. J. Neurosci., 23, 7889-7896.
7. Strittmatter, W.J., Weisgraber, K.H., Huang, D.Y., Dong, L.M., Salvesen, G.S., Pericak-Vance, M., Schmechel, D., Saunders, A.M., Goldgaber, D. and Roses, A.D. (1993) Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc. Natl. Acad. Sci. USA, 90, 8098-8102.
8. Kounnas, M.Z., Moir, R.D., Rebeck, G.W., Bush, A.I., Argraves, W.S., Tanzi, R.E., Hyman, B.T. and Strickland, D.K. (1995) LDL receptor-related protein, a multifunctional ApoE receptor, binds secreted beta-amyloid precursor protein and mediates its degradation. Cell, 82, 331-340.
9. Castellano, J.M., Kim, J., Stewart, F.R., Jiang, H., DeMattos, R.B., Patterson, B.W., Fagan, A.M., Morris, J.C., Mawuenyega, K.G., Cruchaga, C. et al. (2011) Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. Sci. Transl. Med., 3, 89ra57.
10. Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M.L., Pahwa, J.S., Moskvina, V., Dowzell, K., Williams, A. et al. (2009) Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat. Genet., 41, 1088-1093.
11. Hollingworth, P., Harold, D., Sims, R., Gerrish, A., Lambert, J.C., Carrasquillo, M.M., Abraham, R., Hamshere, M.L., Pahwa, J.S., Moskvina, V. et al. (2011) Common variants at ABCA7, MS4A6A/ MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat. Genet., 43, 429-435.
12. Naj, A.C., Jun, G., Beecham, G.W., Wang, L.S., Vardarajan, B.N., Buros, J., Gallins, P.J., Buxbaum, J.D., Jarvik, G.P., Crane, P.K. et al. (2011) Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat. Genet., 43, 436-441.
13. Cruchaga, C., Kauwe, J.S., Mayo, K., Spiegel, N., Bertelsen, S., Nowotny, P., Shah, A.R., Abraham, R., Hollingworth, P., Harold, D. et al. (2010) SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease. PLoS Genet., 6, pii: e1001101.
14. Kauwe, J.S., Jacquart, S., Chakraverty, S., Wang, J., Mayo, K., Fagan, A.M., Holtzman, D.M., Morris, J.C. and Goate, A.M. (2007) Extreme cerebrospinal fluid amyloid beta levels identify family with late-onset Alzheimer's disease presenilin 1 mutation. Ann. Neurol., 61, 446-453.
15. Kauwe, J.S., Cruchaga, C., Mayo, K., Fenoglio, C., Bertelsen, S., Nowotny, P., Galimberti, D., Scarpini, E., Morris, J.C., Fagan, A.M. et al. (2008) Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition. Proc. Natl. Acad. Sci. USA, 105, 8050-8054.
16. Eto, M., Watanabe, K., Iwashima, Y., Morikawa, A., Oshima, E., Sekiguchi, M. and Ishii, K. (1986) Apolipoprotein E phenotypes and plasma lipids in young and middle-aged subjects. Tohoku. J. Exp. Med., 148, 25-34.
17. Gregg, R.E., Zech, L.A., Schaefer, E.J., Stark, D., Wilson, D. and Brewer, H.B. Jr. (1986) Abnormal in vivo metabolism of apolipoprotein E4 in humans. J. Clin. Invest., 78, 815-821.
18. Terrisse, L., Poirier, J., Bertrand, P., Merched, A., Visvikis, S., Siest, G., Milne, R. and Rassart, E. (1998) Increased levels of apolipoprotein D in cerebrospinal fluid and hippocampus of Alzheimer's patients. J. Neurochem., 71, 1643-1650.
19. Danik, M., Champagne, D., Petit-Turcotte, C., Beffert, U. and Poirier, J. (1999) Brain lipoprotein metabolism and its relation to neurodegenerative disease. Crit. Rev. Neurobiol., 13, 357-407.
20. Fukumoto, H., Ingelsson, M., Garevik, N., Wahlund, L.O., Nukina, N., Yaguchi, Y., Shibata, M., Hyman, B.T., Rebeck, G.W. and Irizarry, M.C. (2003) APOE epsilon 3/ epsilon 4 heterozygotes have an elevated proportion of apolipoprotein E4 in cerebrospinal fluid relative to plasma, independent of Alzheimer's disease diagnosis. Exp. Neurol., 183, 249-253.
21. Riddell, D.R., Zhou, H., Atchison, K., Warwick, H.K., Atkinson, P.J., Jefferson, J., Xu, L., Aschmies, S., Kirksey, Y., Hu, Y. et al. (2008) Impact of apolipoprotein E (ApoE) polymorphism on brain ApoE levels. J. Neurosci., 28, 11445-11453.
22. Gupta, V.B., Laws, S.M., Villemagne, V.L., Ames, D., Bush, A.I., Ellis, K.A., Lui, J.K., Masters, C., Rowe, C.C., Szoeke, C. et al. (2011) Plasma apolipoprotein E and Alzheimer disease risk: the AIBL study of aging. Neurology, 76, 1091-1098.
23. Bekris, L.M., Millard, S.P., Galloway, N.M., Vuletic, S., Albers, J.J., Li, G., Galasko, D.R., DeCarli, C., Farlow, M.R., Clark, C.M. et al. (2008) Multiple SNPs within and surrounding the apolipoprotein E gene influence cerebrospinal fluid apolipoprotein E protein levels. J. Alzheimers Dis., 13, 255-266.
24. Wahrle, S.E., Shah, A.R., Fagan, A.M., Smemo, S., Kauwe, J.S., Grupe, A., Hinrichs, A., Mayo, K., Jiang, H., Thal, L.J. et al. (2007) Apolipoprotein E levels in cerebrospinal fluid and the effects of ABCA1 polymorphisms. Mol. Neurodegener., 2, 7.
25. Schneider, J.A., Aggarwal, N.T., Barnes, L., Boyle, P. and Bennett, D.A. (2009) The neuropathology of older persons with and without dementia from community versus clinic cohorts. J. Alzheimers Dis., 18, 691-701.
26. Price, J.L. and Morris, J.C. (1999) Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann. Neurol., 45, 358-368.
27. Fagan, A.M., Mintun, M.A., Mach, R.H., Lee, S.Y., Dence, C.S., Shah, A.R., LaRossa, G.N., Spinner, M.L., Klunk, W.E., Mathis, C.A. et al. (2006) Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann. Neurol., 59, 512-519.
28. Jagust, W.J., Landau, S.M., Shaw, L.M., Trojanowski, J.Q., Koeppe, R.A., Reiman, E.M., Foster, N.L., Petersen, R.C., Weiner, M.W., Price, J.C. et al. (2009) Relationships between biomarkers in aging and dementia. Neurology, 73, 1193-1199.
29. Tapiola, T., Alafuzoff, I., Herukka, S.K., Parkkinen, L., Hartikainen, P., Soininen, H. and Pirttila, T. (2009) Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch. Neurol., 66, 382-389.
30. Nitsch, D., Molokhia, M., Smeeth, L., DeStavola, B.L., Whittaker, J.C. and Leon, D.A. (2006) Limits to causal inference based on Mendelian randomization: a comparison with randomized controlled trials. Am. J. Epidemiol., 163, 397-403.
31. Didelez, V. and Sheehan, N. (2007) Mendelian randomization as an instrumental variable approach to causal inference. Stat. Methods Med. Res., 16, 309-330.
32. Roses, A.D., Lutz, M.W., Amrine-Madsen, H., Saunders, A.M., Crenshaw, D.G., Sundseth, S.S., Huentelman, M.J., Welsh-Bohmer, K.A. and Reiman, E.M. (2010) A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's disease. Pharmacogenomics J., 10, 375-384.
33. Cruchaga, C., Nowotny, P., Kauwe, J.S., Ridge, P.G., Mayo, K., Bertelsen, S., Hinrichs, A., Fagan, A.M., Holtzman, D.M., Morris, J.C. et al. (2011) Association and expression analyses with single-nucleotide polymorphisms in TOMM40 in Alzheimer disease. Arch. Neurol., 68, 1013-1019.
34. Yang, J., Manolio, T.A., Pasquale, L.R., Boerwinkle, E., Caporaso, N., Cunningham, J.M., de Andrade, M., Feenstra, B., Feingold, E., Hayes, M.G. et al. (2011) Genome partitioning of genetic variation for complex traits using common SNPs. Nat. Genet., 43, 519-525.
35. Linton, M.F., Gish, R., Hubl, S.T., Butler, E., Esquivel, C., Bry, W.I., Boyles, J.K., Wardell, M.R. and Young, S.G. (1991) Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation. J. Clin. Invest., 88, 270-281.
36. Fagan, A.M., Roe, C.M., Xiong, C., Mintun, M.A., Morris, J.C. and Holtzman, D.M. (2007) Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch. Neurol., 64, 343-349.
37. Fagan, A.M., Head, D., Shah, A.R., Marcus, D., Mintun, M., Morris, J.C. and Holtzman, D.M. (2009) Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann. Neurol., 65, 176-183.
38. Snider, B.J., Fagan, A.M., Roe, C., Shah, A.R., Grant, E.A., Xiong, C., Morris, J.C. and Holtzman, D.M. (2009) Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. Arch. Neurol., 66, 638-645.
39. Mahley, R.W., Huang, Y. and Rall, S.C. Jr. (1999) Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes. J. Lipid. Res., 40, 1933-1949.
40. Mamotte, C.D., Sturm, M., Foo, J.I., van Bockxmeer, F.M. and Taylor, R.R. (1999) Comparison of the LDL-receptor binding of VLDL and LDL from apoE4 and apoE3 homozygotes. Am. J. Physiol., 276, E553-E557.
41. Altenburg, M., Arbones-Mainar, J., Johnson, L., Wilder, J. and Maeda, N. (2008) Human LDL receptor enhances sequestration of ApoE4 and VLDL remnants on the surface of hepatocytes but not their internalization in mice. Arterioscler. Thromb. Vasc. Biol., 28, 1104-1110.
42. Baulande, S. and Langlois, C. (2010) Proteins sharing PNPLA domain, a new family of enzymes regulating lipid metabolism. Med. Sci., 26, 177-184.
43. Drogan, D., Sheldrick, A.J., Schutze, M., Knuppel, S., Andersohn, F., di Giuseppe, R., Herrmann, B., Willich, S.N., Garbe, E., Bergmann, M.M. et al. (2012) Alcohol consumption, genetic variants in alcohol deydrogenases, and risk of cardiovascular diseases: a prospective study and meta-analysis. PLoS ONE, 7, e32176.
44. Manso, H., Krug, T., Sobral, J., Albergaria, I., Gaspar, G., Ferro, J.M., Oliveira, S.A. and Vicente, A.M. (2012) Variants within the nitric oxide synthase 1 gene are associated with stroke susceptibility. Atherosclerosis, 220, 443-448.
45. Shaw, L.M., Vanderstichele, H., Knapik-Czajka, M., Clark, C.M., Aisen, P.S., Petersen, R.C., Blennow, K., Soares, H., Simon, A., Lewczuk, P. et al. (2009) Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann. Neurol, 65, 403-413.
46. Berg, L., McKeel, D.W. Jr, Miller, J.P., Storandt, M., Rubin, E.H., Morris, J.C., Baty, J., Coats, M., Norton, J., Goate, A.M. et al. (1998) Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch. Neurol., 55, 326-335.
47. McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D. and Stadlan, E.M. (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology, 34, 939-944.
48. Cruchaga, C., Fernandez-Seara, M.A., Seijo-Martinez, M., Samaranch, L., Lorenzo, E., Hinrichs, A., Irigoyen, J., Maestro, C., Prieto, E., Marti-Climent, J.M. et al. (2009) Cortical atrophy and language network reorganization associated with a novel progranulin mutation. Cereb. Cortex., 19, 1751-1760.
49. Koch, W., Ehrenhaft, A., Griesser, K., Pfeufer, A., Muller, J., Schomig, A. and Kastrati, A. (2002) TaqMan systems for genotyping of disease-related polymorphisms present in the gene encoding apolipoprotein E. Clin. Chem. Lab. Med., 40, 1123-1131.
50. Kauwe, J.S., Cruchaga, C., Bertelsen, S., Mayo, K., Latu, W., Nowotny, P., Hinrichs, A.L., Fagan, A.M., Holtzman, D.M. and Goate, A.M. (2010) Validating predicted biological effects of Alzheimer's disease associated SNPs using CSF biomarker levels. J. Alzheimers Dis., 21, 833-842.
51. Cruchaga, C., Graff, C., Chiang, H.H., Wang, J., Hinrichs, A.L., Spiegel, N., Bertelsen, S., Mayo, K., Norton, J.B., Morris, J.C. et al. (2011) Association of TMEM106B gene polymorphism with age at onset in granulin mutation carriers and plasma granulin protein levels. Arch. Neurol, 68, 581-586.
52. Cruchaga, C., Haller, G., Chakraverty, S., Mayo, K., Vallania, F.L., Mitra, R.D., Faber, K., Williamson, J., Bird, T., Diaz-Arrastia, R. et al. (2012) Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in lateonset Alzheimer's disease families. PLoS One, 7, e31039.
53. Price, A.L., Patterson, N.J., Plenge, R.M., Weinblatt, M.E., Shadick, N.A. and Reich, D. (2006) Principal components analysis corrects for stratification in genome-wide association studies. Nat. Genet., 38, 904-909.
54. Muller, P.Y., Janovjak, H., Miserez, A.R. and Dobbie, Z. (2002) Processing of gene expression data generated by quantitative real-time RT-PCR. Biotechniques, 32, 1372-1374, 1376, 1378-1379.
55. Kauwe, J.S., Cruchaga, C., Karch, C.M., Sadler, B., Lee, M., Mayo, K., Latu, W., Su'a, M., Fagan, A.M., Holtzman, D.M. et al. (2011) Fine mapping of genetic variants in BIN1, CLU, CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimer's disease. PLoS ONE, 6, e15918.
56. Voight, B.F., Peloso, G.M., Orho-Melander, M., Frikke-Schmidt, R., Barbalic, M., Jensen, M.K., Hindy, G., Holm, H., Ding, E.L., Johnson, T. et al. (2012) Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study. Lancet.
57. Lawlor, D.A., Harbord, R.M., Sterne, J.A., Timpson, N. and Davey Smith, G. (2008) Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat. Med., 27, 1133-1163.
58. Timpson, N.J., Lawlor, D.A., Harbord, R.M., Gaunt, T.R., Day, I.N., Palmer, L.J., Hattersley, A.T., Ebrahim, S., Lowe, G.D., Rumley, A. et al. (2005) C-reactive protein and its role in metabolic syndrome: Mendelian randomisation study. Lancet, 366, 1954-1959.
59. Conde, L., Vaquerizas, J.M., Dopazo, H., Arbiza, L., Reumers, J., Rousseau, F., Schymkowitz, J. and Dopazo, J. (2006) PupaSuite: finding functional single nucleotide polymorphisms for large-scale genotyping purposes. Nucleic. Acids Res., 34, W621-W625.